Total Payments
$88,107
2024 Payments
$21,596
Companies
8
Transactions
54
Medicare Patients
657
Medicare Billing
$43,808
Payment Breakdown by Category
Research$49,032 (55.7%)
Other$35,442 (40.2%)
Consulting$2,000 (2.3%)
Travel$1,033 (1.2%)
Food & Beverage$383.22 (0.4%)
Education$217.60 (0.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $49,032 | 32 | 55.7% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $34,941 | 7 | 39.7% |
| Consulting Fee | $2,000 | 1 | 2.3% |
| Travel and Lodging | $1,033 | 3 | 1.2% |
| Grant | $500.81 | 1 | 0.6% |
| Food and Beverage | $383.22 | 5 | 0.4% |
| Education | $217.60 | 5 | 0.2% |
Payments by Type
Research
$49,032
32 transactions
General
$39,076
22 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $37,053 | 15 | $0 (2024) |
| CSL Behring | $30,593 | 6 | $0 (2024) |
| PFIZER INC. | $13,873 | 20 | $0 (2024) |
| GENZYME CORPORATION | $5,852 | 7 | $0 (2023) |
| Novo Nordisk Inc | $500.81 | 1 | $0 (2020) |
| Genentech, Inc. | $149.85 | 3 | $0 (2021) |
| E.R. Squibb & Sons, L.L.C. | $42.91 | 1 | $0 (2017) |
| SOBI, INC | $42.50 | 1 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $21,596 | 17 | CSL Behring ($13,235) |
| 2023 | $15,582 | 10 | CSL Behring ($6,057) |
| 2022 | $10,476 | 3 | CSL Behring ($6,400) |
| 2021 | $149.85 | 3 | Genentech, Inc. ($149.85) |
| 2020 | $14,072 | 9 | Novartis Pharmaceuticals Corporation ($8,707) |
| 2019 | $1,512 | 3 | NOVARTIS PHARMACEUTICALS CORPORATION ($1,499) |
| 2018 | $2,152 | 4 | GENZYME CORPORATION ($2,152) |
| 2017 | $22,568 | 5 | NOVARTIS PHARMACEUTICALS CORPORATION ($21,557) |
All Payment Transactions
54 individual payment records from CMS Open Payments — Page 1 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/07/2024 | PFIZER INC. | BENEFIX (Biological), BEQVEZ | — | In-kind items and services | $940.00 | Research |
| Study: BENEFIX CLINICAL PUBLICATION PROGRAM • Category: HEMATOLOGY | ||||||
| 10/22/2024 | PFIZER INC. | BENEFIX (Biological), BEQVEZ | — | In-kind items and services | $330.00 | Research |
| Study: BENEFIX CLINICAL PUBLICATION PROGRAM • Category: HEMATOLOGY | ||||||
| 10/22/2024 | PFIZER INC. | BENEFIX (Biological), BEQVEZ | — | In-kind items and services | $330.00 | Research |
| Study: BENEFIX CLINICAL PUBLICATION PROGRAM • Category: HEMATOLOGY | ||||||
| 10/18/2024 | PFIZER INC. | BENEFIX (Biological), BEQVEZ | — | In-kind items and services | $330.00 | Research |
| Study: BENEFIX CLINICAL PUBLICATION PROGRAM • Category: HEMATOLOGY | ||||||
| 07/31/2024 | PFIZER INC. | BENEFIX (Biological), XYNTHA | — | In-kind items and services | $330.00 | Research |
| Study: NONACOG ALFA CLINICAL PUBLICATION PROGRAM • Category: HEMATOLOGY | ||||||
| 07/31/2024 | PFIZER INC. | BENEFIX (Biological), XYNTHA | — | In-kind items and services | $330.00 | Research |
| Study: NONACOG ALFA CLINICAL PUBLICATION PROGRAM • Category: HEMATOLOGY | ||||||
| 07/31/2024 | PFIZER INC. | BENEFIX (Biological), XYNTHA | — | In-kind items and services | $330.00 | Research |
| Study: NONACOG ALFA CLINICAL PUBLICATION PROGRAM • Category: HEMATOLOGY | ||||||
| 07/31/2024 | PFIZER INC. | BENEFIX (Biological), XYNTHA | — | In-kind items and services | $330.00 | Research |
| Study: NONACOG ALFA CLINICAL PUBLICATION PROGRAM • Category: HEMATOLOGY | ||||||
| 07/31/2024 | PFIZER INC. | BENEFIX (Biological), XYNTHA | — | In-kind items and services | $330.00 | Research |
| Study: NONACOG ALFA CLINICAL PUBLICATION PROGRAM • Category: HEMATOLOGY | ||||||
| 06/24/2024 | PFIZER INC. | XYNTHA (Biological) | — | In-kind items and services | $940.00 | Research |
| Study: MOROCTOCOG ALFA CLINICAL PUBLICATION PROGRAM • Category: HEMATOLOGY | ||||||
| 03/10/2024 | CSL Behring | Kcentra (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $13,235.00 | General |
| Category: Trauma (Emergency, Injury, Surgery) | ||||||
| 03/05/2024 | PFIZER INC. | BEQVEZ (Biological) | Consulting Fee | Cash or cash equivalent | $2,000.00 | General |
| Category: HEMATOLOGY | ||||||
| 02/07/2024 | PFIZER INC. | XYNTHA (Biological), BENEFIX | — | In-kind items and services | $940.00 | Research |
| Study: PF05230907 PF05280602 GIROCTOCOGENE FITELPARVOVEC FIDANACOGENE ELAPARVOVEC MARSTACIMAB MOROCTOCOG ALFA MULTI PRODUCT NONACOG ALFA CLINICAL PUBLICATION PROGRAM • Category: HEMATOLOGY | ||||||
| 01/17/2024 | PFIZER INC. | XYNTHA (Biological), BENEFIX | — | In-kind items and services | $330.00 | Research |
| Study: PF05230907 PF05280602 GIROCTOCOGENE FITELPARVOVEC FIDANACOGENE ELAPARVOVEC MARSTACIMAB MOROCTOCOG ALFA MULTI PRODUCT NONACOG ALFA CLINICAL PUBLICATION PROGRAM • Category: HEMATOLOGY | ||||||
| 01/17/2024 | Novartis Pharmaceuticals Corporation | — | — | Cash or cash equivalent | $198.06 | Research |
| Study: CVAY736I12301- VAYHIT1,CVAY736Q12301- VAYHIT2, CVAY736Q12201- VAYHIT3 | ||||||
| 01/17/2024 | SOBI, INC | DOPTELET (Drug) | Food and Beverage | In-kind items and services | $42.50 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 01/16/2024 | PFIZER INC. | XYNTHA (Biological), BENEFIX | — | In-kind items and services | $330.00 | Research |
| Study: PF05230907 PF05280602 GIROCTOCOGENE FITELPARVOVEC FIDANACOGENE ELAPARVOVEC MARSTACIMAB MOROCTOCOG ALFA MULTI PRODUCT NONACOG ALFA CLINICAL PUBLICATION PROGRAM • Category: HEMATOLOGY | ||||||
| 12/07/2023 | Novartis Pharmaceuticals Corporation | — | Travel and Lodging | Cash or cash equivalent | $514.17 | General |
| 12/07/2023 | Novartis Pharmaceuticals Corporation | — | Travel and Lodging | In-kind items and services | $291.89 | General |
| 12/07/2023 | Novartis Pharmaceuticals Corporation | — | Food and Beverage | In-kind items and services | $210.12 | General |
| 10/25/2023 | PFIZER INC. | — | — | In-kind items and services | $330.00 | Research |
| Study: PF05280602 CLINICAL PUBLICATION PROGRAM | ||||||
| 07/28/2023 | GENZYME CORPORATION | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,769.00 | General |
| 05/15/2023 | PFIZER INC. | — | — | In-kind items and services | $3,200.00 | Research |
| Study: FIDANACOGENE ELAPARVOVEC CLINICAL PUBLICATION PROGRAM | ||||||
| 05/10/2023 | CSL Behring | Kcentra (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $6,056.60 | General |
| Category: Trauma (Emergency, Injury, Surgery) | ||||||
| 01/18/2023 | PFIZER INC. | BENEFIX | — | In-kind items and services | $940.00 | Research |
| Study: MOROCTOCOG ALFA CLINICAL PUBLICATION PROGRAM | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| RESEARCH RELATED PUBLICATION SUPPORT | NOVARTIS PHARMACEUTICALS CORPORATION | $21,557 | 1 |
| RESEARCH RELATED PUBLICATIONS SUPPORT | Novartis Pharmaceuticals Corporation | $8,596 | 5 |
| PUBLICATION SUPPORT PROVIDED IN CONNECTION WITH HEOR RESEARCH | NOVARTIS PHARMACEUTICALS CORPORATION | $4,025 | 1 |
| FIDANACOGENE ELAPARVOVEC CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $3,200 | 1 |
| MOROCTOCOG ALFA CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $3,150 | 4 |
| BENEFIX CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $1,930 | 4 |
| NONACOG ALFA CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $1,650 | 5 |
| PF05230907 PF05280602 GIROCTOCOGENE FITELPARVOVEC FIDANACOGENE ELAPARVOVEC MARSTACIMAB MOROCTOCOG ALFA MULTI PRODUCT NONACOG ALFA CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $1,600 | 3 |
| RESEARCH RELATED PUBLICATIONS SUPPORT | NOVARTIS PHARMACEUTICALS CORPORATION | $1,499 | 2 |
| CAMMS323 - CARE-MS I, CAMMS324 - CARE-MS II, and CAMMS3409 - CARE-MS Extension | GENZYME CORPORATION | $478.61 | 1 |
| An Extension Protocol for Multiple Sclerosis patients Who Participated in Genzyme-sponsored Studies of Alemtuzumab | GENZYME CORPORATION | $452.74 | 1 |
| PF05280602 CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $330.00 | 1 |
| An Extension Protocol for Multiple Sclerosis Patients Who Participated in Genzyme-Sponsored Studies of Alemtuzumab | GENZYME CORPORATION | $219.90 | 1 |
| CVAY736I12301- VAYHIT1,CVAY736Q12301- VAYHIT2, CVAY736Q12201- VAYHIT3 | Novartis Pharmaceuticals Corporation | $198.06 | 1 |
| An Extension Protocol for Multiple Sclerosis Patients Who Participated in Genzyme-sponsored Studies of Alemtuzumab | GENZYME CORPORATION | $145.20 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 4 | 171 | 179 | $38,678 | $11,626 |
| 2022 | 3 | 155 | 160 | $28,013 | $9,861 |
| 2021 | 4 | 200 | 210 | $39,495 | $14,486 |
| 2020 | 3 | 131 | 138 | $24,640 | $7,834 |
Total Patients
657
Total Services
687
Medicare Billing
$43,808
Procedure Codes
14
All Medicare Procedures & Services
14 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 76 | 80 | $13,355 | $5,305 | 39.7% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 18 | 18 | $7,664 | $2,417 | 31.5% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 20 | 20 | $7,960 | $2,125 | 26.7% |
| 85390 | Coagulation function screening test with interpretation and report | Facility | 2023 | 57 | 61 | $9,699 | $1,779 | 18.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 73 | 78 | $11,055 | $5,175 | 46.8% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 20 | 20 | $7,100 | $2,760 | 38.9% |
| 85390 | Coagulation function screening test with interpretation and report | Facility | 2022 | 62 | 62 | $9,858 | $1,925 | 19.5% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 64 | 67 | $9,510 | $5,022 | 52.8% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 27 | 27 | $9,715 | $4,268 | 43.9% |
| 85390 | Coagulation function screening test with interpretation and report | Facility | 2021 | 98 | 105 | $16,695 | $3,335 | 20.0% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 11 | 11 | $3,575 | $1,862 | 52.1% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 47 | 50 | $7,000 | $2,923 | 41.8% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Facility | 2020 | 18 | 18 | $6,510 | $2,630 | 40.4% |
| 85390 | Coagulation function screening test with interpretation and report | Facility | 2020 | 66 | 70 | $11,130 | $2,281 | 20.5% |
About Dr. Adam Cuker, MD
Dr. Adam Cuker, MD is a Hematology & Oncology healthcare provider based in Philadelphia, Pennsylvania. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 12/19/2006. The National Provider Identifier (NPI) number assigned to this provider is 1457414625.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Adam Cuker, MD has received a total of $88,107 in payments from pharmaceutical and medical device companies, with $21,596 received in 2024. These payments were reported across 54 transactions from 8 companies. The most common payment nature is "" ($49,032).
As a Medicare-enrolled provider, Cuker has provided services to 657 Medicare beneficiaries, totaling 687 services with total Medicare billing of $43,808. Data is available for 4 years (2020–2023), covering 14 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Other Specialties Hematology & Oncology, Hematology
- Location Philadelphia, PA
- Active Since 12/19/2006
- Last Updated 04/10/2012
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1457414625
Products in Payments
- Kcentra (Biological) $30,501
- PROMACTA (Drug) $28,792
- BENEFIX (Biological) $3,580
- LEMTRADA (Drug) $3,083
- XYNTHA (Biological) $2,553
- BEQVEZ (Biological) $2,000
- HEMLIBRA (Biological) $149.85
- Idelvion (Biological) $55.00
- DOPTELET (Drug) $42.50
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Philadelphia
Shayma Kazmi, Md, MD
Hematology & Oncology — Payments: $715,210
Hematology & Oncology $715,210
Charu Aggarwal, Md, Mph, MD, MPH
Hematology & Oncology — Payments: $510,275
Hematology & Oncology $510,275
Dr. Catherine Lai, M.d., M.p.h, M.D., M.P.H
Hematology & Oncology — Payments: $249,951
Hematology & Oncology $249,951
Dr. Martin Edelman, M.d, M.D
Hematology & Oncology — Payments: $207,464
Hematology & Oncology $207,464
Keith Pratz, M.d, M.D
Hematology & Oncology — Payments: $175,955
Hematology & Oncology $175,955
David Porter, Md, MD
Hematology & Oncology — Payments: $173,636
Hematology & Oncology $173,636